Very high levels of PSA in patients with cardiogenic shock: Report of four clinical cases.

Cardiogenic shock PSA Prostate Cancer Screening Prostate cancer Prostate specific antigen

Journal

Clinical biochemistry
ISSN: 1873-2933
Titre abrégé: Clin Biochem
Pays: United States
ID NLM: 0133660

Informations de publication

Date de publication:
Feb 2020
Historique:
received: 10 09 2019
revised: 31 10 2019
accepted: 06 11 2019
pubmed: 26 11 2019
medline: 18 2 2020
entrez: 26 11 2019
Statut: ppublish

Résumé

Prostate-specific antigen (PSA) is the tumor marker most widely used in conjunction with digital rectal examination (DRE) for the early detection of prostate cancer (PCa). Due to its limitations, especially the high rate of false positive (FP) results, PSA screening of transplant candidates is a controversial issue. Moreover, obtaining a FP result in the PCa screening of heart transplant candidates may lead to potentially harmful effects. Although most of the factors that may cause PSA FP results are well known, FP results related to cardiogenic shock, a common indication for heart transplant, are less known. We studied retrospectively four patients who suffered cardiogenic shock during their hospital stay and became heart transplant candidates. Their PSA serum levels were very high suggesting the presence of PCa. Our findings have shown that elevated PSA serum levels in these patients were not related to PCa and they might be associated with cardiogenic shock. This clinical case study adds evidences to the fact that cardiogenic shock is an important cause of PSA FP results, therefore it cannot be used as a reliable marker of PCa in this clinical condition and positive results should be properly interpreted.

Identifiants

pubmed: 31765638
pii: S0009-9120(19)30985-3
doi: 10.1016/j.clinbiochem.2019.11.002
pii:
doi:

Substances chimiques

Prostate-Specific Antigen EC 3.4.21.77

Types de publication

Case Reports

Langues

eng

Sous-ensembles de citation

IM

Pagination

42-44

Informations de copyright

Copyright © 2019 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Esther Fernández-Galán (E)

Department of Biochemistry and Molecular Genetics (CDB), Hospital Clínic of Barcelona, Barcelona, Spain. Electronic address: esfernandez@clinic.cat.

Josep M Augé (JM)

Department of Biochemistry and Molecular Genetics (CDB), Hospital Clínic of Barcelona, Barcelona, Spain.

Rafael Molina (R)

Department of Biochemistry and Molecular Genetics (CDB), Hospital Clínic of Barcelona, Barcelona, Spain.

Xavier Filella (X)

Department of Biochemistry and Molecular Genetics (CDB), Hospital Clínic of Barcelona, Barcelona, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH